Review
Published on 19 Jul 2019
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2019.01574
- 26,508 views
- 76 citations
